When the new COVID-19 vaccines were introduced two years ago, public health experts saw an increase in incidences of myocarditis, an inflammation of the heart muscle, particularly among young guys who had received mRNA immunizations. However, it was unclear what was triggering this reaction.
Yale researchers have found the immunological profile of these heart inflammatory cases in a recent study.
These findings, which were published on May 5 in the journal Science Immunology, rule out some of the previously proposed causes of heart inflammation and provide potential approaches to further minimize the occurrence of a yet uncommon adverse effect of vaccination, according to the scientists.
Myocarditis is a moderate inflammation of heart tissue that might cause scarring but normally resolves within a few days. The increased prevalence of myocarditis during vaccination was noticed largely among males in their teens or early twenties who had been vaccinated with mRNA vaccines, which are designed to elicit immunological responses specific to the SARS-CoV-2 virus.
According to the Centers for Disease Control and Prevention (CDC), 22 to 36 males aged 12 to 17 had myocarditis within 21 days of receiving a second vaccination dose. After infection with the COVID-19 virus, the incidence of myocarditis among uninfected males in this age group ranged from 50.1 to 64.9 cases per 100,000.
The Yale research team conducted a rigorous investigation of immune system responses in those uncommon incidences of myocarditis among vaccinated individuals for the new study. Carrie Lucas, an assistant professor of immunobiology, Akiko Iwasaki, the Sterling Professor of Immunobiology, and Inci Yildirim, an associate professor of pediatrics and epidemiology, led the team.
They discovered that the heart inflammation was triggered by a more widespread reaction involving immune cells and inflammation, rather than by antibodies produced by the vaccine.
“The immune systems of these individuals get a little too revved up and over-produce cytokine and cellular responses,” Lucas said.
Previous studies revealed that lengthening the interval between immunization doses from four to eight weeks may lower the chance of acquiring myocarditis.
According to CDC data, the risk of myocarditis among unprotected individuals who get the COVID-19 virus is much higher than in those who receive immunizations. She stressed that vaccination is the greatest way to prevent COVID-19-related sickness.
“I hope this new knowledge will enable further optimizing mRNA vaccines, which, in addition to offering clear health benefits during the pandemic, have a tremendous potential to save lives across numerous future applications,” said Anis Barmada, an M.D./Ph.D. student at Yale School of Medicine, who is a co-first author of the paper with Jon Klein, also a Yale M.D./Ph.D. student.
more recommended stories
Oligometastatic Pancreatic Cancer: New Global ConsensusKey Points Summary An international expert.
Endometriosis Screening Tool May Cut Diagnosis DelaysKey Points Researchers from the University.
Influenza Vulnerability Index Maps Flu Risk Across US StatesKey Points Researchers developed a new.
Post Amputation Pain Patterns Differ by Prosthetic TypeKey Summary A new study from.
Diabetic Kidney Disease: Combo Therapy Targets Zombie CellsKey Points Researchers from Mayo Clinic.
Heart Attack Recovery: Single Injection May Heal the HeartKey Points Researchers have developed a.
Fragmentome Technology Detects Early Liver FibrosisKey Points at a Glance AI-based.
CTNNB1 Syndrome Study Explores Beta-Catenin DefectsKey Takeaways Researchers in Spain are.
Tuberculosis Breakthrough with Experimental AntibioticsKey Takeaways Experimental antibiotics disrupt a.
National Healthy Longevity Trial Receives Federal SupportKey Summary Up to $38 million.

Leave a Comment